Jaguar Health is trading lower after the company announced its phase 3 OnTarget trial results for Crofelemer did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Jaguar Health's stock is trading lower following the announcement that its phase 3 OnTarget trial results for Crofelemer did not meet the primary endpoint.
July 23, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jaguar Health's phase 3 OnTarget trial for Crofelemer did not meet its primary endpoint, leading to a decline in the stock price.
The failure to meet the primary endpoint in a phase 3 trial is a significant setback for any biotech company, as it raises concerns about the efficacy of the drug and its potential for FDA approval. This news is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100